Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 12-Sep-2012; this decision was made due to poor recruitment and overall business strategy. The study was not terminated for safety reasons nor for lack of efficacy.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and/or Females between 18-65 years, inclusive.
Body mass index of 18.5 to 45.4 kg/m2 at screening, inclusive. body weight equals or greater than 110 lb.
Have type 2 diabetes mellitus.
On stable dose of anti-diabetic and anti-hypertensive medication prior to screening.
You may not be if
Recent evidence or medical history of unstable concurrent disease.
Cardiovascular event within 3 months prior to screening.
History of renal transplant.
History of hospitalization for acute kidney injury or acute kidney dialysis within 6 months prior to screening.
Clareo Health | A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
